E. S. Ford, The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the national health and nutrition examination survey ii mortality study, Atherosclerosis, vol.173, pp.309-314, 2004.

E. S. Ford, W. H. Giles, and A. H. Mokdad, Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care, vol.27, pp.2444-2449, 2004.

B. Isomaa, P. Almgren, and T. Tuomi, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, vol.24, pp.683-689, 2001.

A. Celentano, V. Palmieri, and S. Panico, Individuals' cardiovascular risk profile projected by family doctors and individuals' knowledge of cardiovascular risk factors: a challenge for primary prevention. The cardiovascular risk prevention project "help your heart stay young, Ital Heart J, vol.6, pp.557-564, 2005.

J. D. Knudson, U. D. Dincer, I. N. Bratz, M. Sturek, G. M. Dick et al., Mechanisms of coronary dysfunction in obesity and insulin resistance, Microcirculation, vol.14, pp.317-338, 2007.

J. A. Kim, M. Montagnani, K. K. Koh, and M. J. Quon, Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms, Circulation, vol.113, pp.1888-1904, 2006.

S. Sola, M. Q. Mir, and F. A. Cheema, Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the irbesartan and lipoic acid in endothelial dysfunction (island) study, Circulation, vol.111, pp.343-348, 2005.

S. Messaoudi, F. Azibani, C. Delcayre, and F. Jaisser, Aldosterone, mineralocorticoid receptor, and heart failure, Mol Cell Endocrinol, vol.350, pp.266-272, 2012.

S. Viengchareun, L. Menuet, D. Martinerie, L. Munier, M. et al., The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology, Nucl Recept Signal, vol.5, p.12, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00193515

J. Bauersachs, F. Jaisser, and R. Toto, Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases, Hypertension, vol.65, pp.257-263, 2015.

C. G. Brilla, Renin-angiotensin-aldosterone system and myocardial fibrosis, Cardiovasc Res, vol.47, pp.1-3, 2000.

B. Pitt, F. Zannad, and W. J. Remme, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators, N Engl J Med, vol.341, pp.709-717, 1999.

B. Pitt, G. Williams, and W. Remme, The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study, Cardiovasc Drugs Ther, vol.15, pp.79-87, 2001.

B. Pitt, W. Remme, and F. Zannad, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, vol.348, pp.1309-1321, 2003.

F. Zannad, J. J. Mcmurray, and H. Krum, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, vol.364, issue.1, pp.11-21, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01742988

L. Barfacker, A. Kuhl, and A. Hillisch, Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases, ChemMedChem, vol.7, pp.1385-1403, 2012.

L. Amazit, L. Billan, F. Kolkhof, and P. , Finerenone Impedes Aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1, J Biol Chem, vol.290, pp.21876-21889, 2015.

P. Kolkhof, M. Delbeck, and A. Kretschmer, Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury, J Cardiovasc Pharmacol, vol.64, pp.69-78, 2014.

J. Grune, N. Beyhoff, and E. Smeir, Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity, Hypertension, vol.71, pp.599-608, 2018.

Y. Fang, L. Nicol, and N. Harouki, Improvement of left ventricular diastolic function induced by beta-blockade, J Mol Cell Cardiol, vol.51, pp.168-176, 2011.

E. Turkstra, B. Braam, and H. A. Koomans, Impaired renal blood flow autoregulation in two-kidney, one-clip hypertensive rats is caused by enhanced activity of nitric oxide, J Am Soc Nephrol, vol.11, pp.847-855, 2000.

S. E. Litwin, S. E. Katz, J. P. Morgan, and P. S. Douglas, Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat, Circulation, vol.89, pp.345-354, 1994.

P. Mulder, V. Richard, and G. Derumeaux, Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling, Circulation, vol.96, pp.1976-1982, 1997.

D. J. Sahn, A. Demaria, J. Kisslo, and A. Weyman, Recommendations regarding quantitation in m-mode echocardiography: results of a survey of echocardiographic measurements, Circulation, vol.58, pp.1072-1083, 1978.

C. Waller, K. H. Hiller, S. Voll, A. Haase, G. Ertl et al., Myocardial perfusion imaging using a non-contrast agent MR imaging technique, Int J Cardiovasc Imaging, vol.17, pp.123-132, 2001.

F. Kober, I. Iltis, P. J. Cozzone, and M. Bernard, Myocardial blood flow mapping in mice using high-resolution spin labeling magnetic resonance imaging: influence of ketamine/xylazine and isoflurane anesthesia, Magn Reson Med, vol.53, pp.601-606, 2005.
URL : https://hal.archives-ouvertes.fr/hal-02119119

P. Mulder, V. Mellin, and J. Favre, Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone, Eur Heart J, vol.29, pp.2171-2179, 2008.

V. Mellin, M. Isabelle, and A. Oudot, Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure, Eur Heart J, vol.26, pp.1544-1550, 2005.

P. H. Macarthur, S. Shiva, and M. T. Gladwin, Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence, J Chromatogr B Analyt Technol Biomed Life Sci, vol.851, pp.93-105, 2007.

R. J. Henry, M. Segalove, and C. Sobel, Turbidimetric determination of proteins with sulfosalicylic and trichloracetic acids, Proc Soc Exp Biol Med, vol.92, pp.748-751, 1956.

A. Gueret, N. Harouki, and J. Favre, Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction, Hypertension, vol.67, pp.717-723, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02296624

N. Merabet, Y. Fang, and L. Nicol, Selective heart rate reduction improves metabolic syndrome-related left ventricular diastolic dysfunction, J Cardiovasc Pharmacol, vol.66, pp.399-408, 2015.

T. Lauer, M. Preik, and T. Rassaf, Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action, Proc Natl Acad Sci U S A, vol.98, pp.12814-12819, 2001.

J. E. Toblli, G. Cao, J. F. Giani, M. Angerosa, F. P. Dominici et al., Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis, Kidney Blood Press Res, vol.34, pp.20-33, 2012.

I. Palomo, A. Contreras, and L. M. Alarcon, Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome, Nitric Oxide, vol.24, pp.224-228, 2011.

W. J. Paulus and A. M. Shah, No and cardiac diastolic function, Cardiovasc Res, vol.43, pp.595-606, 1999.

L. Van-heerebeek, N. Hamdani, and M. L. Handoko, Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension, Circulation, vol.117, pp.43-51, 2008.

S. B. Bender, V. G. Demarco, and J. Padilla, Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction, Hypertension, vol.65, pp.1082-1088, 2015.

T. C. Gillebert, D. Hert, S. G. Andries, L. J. Jageneau, A. H. Brutsaert et al., Intracavitary ultrasound impairs left ventricular performance: presumed role of endocardial endothelium, Am J Physiol, vol.263, pp.857-865, 1992.

L. Van-heerebeek, A. Somsen, and W. J. Paulus, The failing diabetic heart: focus on diastolic left ventricular dysfunction, Curr Diab Rep, vol.9, pp.79-86, 2009.

M. M. El-omar, R. Lord, N. J. Draper, and A. M. Shah, Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy, Eur J Heart Fail, vol.5, pp.229-239, 2003.

G. A. Silberman, T. H. Fan, and H. Liu, Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction, Circulation, vol.121, pp.519-528, 2010.

C. M. Matter, L. Mandinov, P. A. Kaufmann, G. Vassalli, Z. Jiang et al., Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy, Circulation, vol.99, pp.2396-2401, 1999.

D. Fraccarollo, J. D. Widder, and P. Galuppo, Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction, Circulation, vol.118, pp.818-827, 2008.

S. Serpillon, B. C. Floyd, and R. S. Gupte, Superoxide production by NAD(P) H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH, Am J Physiol Heart Circ Physiol, vol.297, pp.153-162, 2009.

P. Rosen and A. Osmers, Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose, Horm Metab Res, vol.38, pp.575-586, 2006.

X. Zhou, L. Ma, and J. Habibi, Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat, Hypertension, vol.55, pp.880-888, 2010.

S. R. Kapadia, Cytokines and heart failure, Cardiol Rev, vol.7, pp.196-206, 1999.

C. E. Luyt, D. Lepailleur-enouf, C. J. Gaultier, O. Valdenaire, G. Steg et al., Involvement of the endothelin system in experimental critical hind limb ischemia, Mol Med, vol.6, pp.947-956, 2000.

M. Jain, D. A. Brenner, and L. Cui, Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes, Circ Res, vol.93, pp.9-16, 2003.

G. M. Kuster, S. Lancel, and J. Zhang, Redox-mediated reciprocal regulation of SERCA and Na+-Ca2+ exchanger contributes to sarcoplasmic reticulum Ca2+ depletion in cardiac myocytes, Free Radic Biol Med, vol.48, pp.1182-1187, 2010.

M. Maczewski and U. Mackiewicz, Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart, Cardiovasc Res, vol.79, pp.42-51, 2008.

D. A. Siwik, P. J. Pagano, and W. S. Colucci, Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts, Am J Physiol Cell Physiol, vol.280, pp.53-60, 2001.

W. Zhao, T. Zhao, Y. Chen, R. A. Ahokas, and Y. Sun, Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats, Mol Cell Biochem, vol.317, pp.43-50, 2008.

S. Bianchi, R. Bigazzi, and V. M. Campese, Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease, Kidney Int, vol.70, pp.2116-2123, 2006.

G. D. Lopaschuk, C. D. Folmes, and W. C. Stanley, Cardiac energy metabolism in obesity, Circ Res, vol.101, pp.335-347, 2007.

D. J. Chess, B. Lei, B. D. Hoit, A. M. Azimzadeh, and W. C. Stanley, Deleterious effects of sugar and protective effects of starch on cardiac remodeling, contractile dysfunction, and mortality in response to pressure overload, Am J Physiol Heart Circ Physiol, vol.293, pp.1853-1860, 2007.

M. Yamaji, T. Tsutamoto, and C. Kawahara, Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure, Am Heart J, vol.160, pp.915-921, 2010.

F. Zannad, G. Stough, W. Rossignol, and P. , Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice, Eur Heart J, vol.33, pp.2782-2795, 2012.

S. J. Frisbee, S. S. Singh, and D. N. Jackson, Beneficial pleiotropic antidepressive effects of cardiovascular disease risk factor interventions in the metabolic syndrome, J Am Heart Assoc, vol.7, issue.7, p.8185, 2018.

S. D. Brooks, S. M. Hileman, and P. D. Chantler, Protection from vascular dysfunction in female rats with chronic stress and depressive symptoms, Am J Physiol Heart Circ Physiol, vol.314, pp.1070-1084, 2018.

S. D. Brooks, S. M. Hileman, and P. D. Chantler, Protection from chronic stress-and depressive symptom-induced vascular endothelial dysfunction in female rats is abolished by preexisting metabolic disease, Am J Physiol Heart Circ Physiol, vol.314, pp.1085-1097, 2018.

M. Lachaux, J. Barrera-chimal, and L. Nicol, Short-and long-term administration of the nonsteroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
URL : https://hal.archives-ouvertes.fr/inserm-02296612

, Diabetes Obes Metab, vol.20, pp.2399-2407, 2018.